Qritive Raises $7.5 Million in Series A  

by Kay Aloha Villamor in January 10th, 2023

Qritive, a Singapore-based healthcare startup that uses AI to improve cancer diagnosis and patient care, raised $7.5 million in Series A funding.

The round was led by MassMutual Ventures, with participation from SEEDS Capital and Exfinity Venture Partners.

The company will use this new capital to drive geographical expansion, expand the product portfolio, and support regulatory clearances. 

“Complexity of diagnostics has increased considerably and having tools that increase accuracy and throughput really fast has become instrumental for clinicians worldwide.”— Aneesh Sathe, CEO of Qritive

Qritive’s Pantheon digital pathology platform is a one-of-a-kind platform that brings together tools for case management, reporting, slide viewing and analysis, telepathology, synoptic reporting, and LIS integration. 

Qritive’s technology helps accelerate cancer diagnosis across multiple cancer types, including colon, prostate, and lymph node, and includes a robust set of tools for immunohistochemistry. 

Company: Qritive Pte. Ltd.

Raised: $7.5M

Round: Series A 

Funding Month: January 2023

Lead Investors: MassMutual Ventures

Additional Investors: SEEDS Capital and Exfinity Venture Partners

Company Website: https://qritive.com/

Software Category: Digital Pathology 

About the Company: Founded in 2017 by Dr. Aneesh Sathe and Dr. Kaveh Taghipour, Qritive is an artificial intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis, enhancing imaging accuracy, and improving health outcomes with the assistance of AI-based solutions. Using artificial intelligence, Qritive solutions provide fast and accurate interpretations of pathology whole slide image scans within seconds, reducing time to treatment, and increasing accuracy for cancer care. It expands on deep learning technology to provide automated interpretation of pathology tests for time- and resource-strapped medical imaging professionals-enabling faster diagnosis and speed to treatment. Qritive’s solutions are CE-certified and also approved for clinical use by the Singapore Health Sciences Authority (HSA). Qritive is headquartered in Singapore, with offices in the USA and India.

Source: https://world.einnews.com/pr_news/609842708/healthcare-ai-firm-qritive-raises-7-5m-to-expand-into-new-markets

Your cart